SCYX - SCYNEXIS, Inc.
| Previous Close | 1.2200 |
| Open | 1.2100 |
| Bid | 1.2100 x 27000 |
| Ask | 1.4100 x 800 |
| Day's Range | 1.1854 - 1.2300 |
| 52 Week Range | 0.3500 - 1.9000 |
| Volume | 233,220 |
| Avg. Volume | 390,582 |
| Market Cap | 65.991M |
| Beta (3Y Monthly) | 3.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6560 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.58 |
- PR Newswire•20 days ago
X-Biotix Therapeutics Joins Antimicrobials Working Group
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to ...
- PR Newswire•26 days ago
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
JERSEY CITY, N.J., June 25, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the availability of nine presentations (here) from the American Society for Microbiology (ASM) Microbe 2019, which occurred June 20-24, 2019, in San Francisco. Ibrexafungerp (formerly SCY-078), the first representative of a novel triterpenoid antifungal family being developed for oral and intravenous (IV) usage, is in clinical development for the treatment of multiple serious fungal infections, including many that have shown resistance to existing therapies. "Oral ibrexafungerp's potential to address areas of significant unmet medical need is highlighted by the data presented at ASM Microbe," said Luis Ostrosky-Zeichner, MD, a renowned fungal infection expert and investigator in SCYNEXIS' ongoing FURI and SCYNERGIA trials.
- PR Newswire•last month
Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
64 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- Simply Wall St.•last month
Imagine Owning SCYNEXIS (NASDAQ:SCYX) And Trying To Stomach The 84% Share Price Drop
It's nice to see the SCYNEXIS, Inc. (NASDAQ:SCYX) share price up 19% in a week. But will that repair the damage for...
- PR Newswire•last month
SCYNEXIS Appoints Dr. Nkechi Azie as Vice President of Clinical Development
JERSEY CITY, N.J., June 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Nkechi Azie, MD, MBA, FIDSA, as Vice President of Clinical Development, effective June 10, 2019. Dr. Azie will lead clinical development activities and strengthen medical affairs efforts in anticipation of ibrexafungerp's potential approval and commercial launch.
- PR Newswire•last month
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for ...
- PR Newswire•2 months ago
SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
New in vivo studies support potential use of ibrexafungerp in skin and invasive infections caused by multidrug-resistant pathogen, Candida auris New chronic nonclinical toxicity studies demonstrate ibrexafungerp's ...
- PR Newswire•2 months ago
SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
Ibrexafungerp's favorable toxicology and embryofetal toxicity profile provide further differentiation from currently available antifungal treatments Results support long-term dosing of oral ibrexafungerp, ...
- Zacks•2 months ago
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
Scynexis (SCYX) delivered earnings and revenue surprises of -20.00% and -24.71%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Scynexis: 1Q Earnings Snapshot
The Jersey City, New Jersey-based company said it had a loss of 46 cents per share. Losses, adjusted for non-recurring costs and to extinguish debt, came to 24 cents per share. The pharmaceutical company ...
- PR Newswire•2 months ago
SCYNEXIS Reports First Quarter 2019 Financial Results and Provides Company Update
Continued advancement of VVC program, including completed favorable embryo-fetal safety profile, further supports a potential first NDA submission of oral ibrexafungerp in the second half of 2020 Positive ...
- Zacks•2 months ago
Scynexis (SCYX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Scynexis (SCYX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire•2 months ago
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
Complete regulatory embryo-fetal toxicology package shows no adverse fetal effects caused by ibrexafungerp Confirmed antifungal activity of ibrexafungerp against a variety of Candida strains resistant ...
- PR Newswire•3 months ago
SCYNEXIS to Present Data at ACOG 2019 Further Demonstrating the Favorable Profile of Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Presentations to be available on Monday May 6, 2019 JERSEY CITY, N.J. , May 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat ...
- PR Newswire•3 months ago
SCYNEXIS to Discuss ECCMID 2019 Clinical Data, Including Successful Case Studies in Candida auris and Other Difficult-to-Treat Infections, on Conference Call
Global fungal infection thought leaders to participate Call to be held April 15, 2019 at 4:15 p.m. ET JERSEY CITY, N.J. , April 15, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company ...
- Benzinga•3 months ago
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Biotech stocks witnessed a slowdown in momentum last week, which was a relatively slow one in terms of news flow. Amgen, Inc. (NASDAQ: AMGN )'s unique drug to treat osteoporosis in postmenopausal women ...
- PR Newswire•3 months ago
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
78 Presentations by Coalition Members During the Annual Meeting WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant ...
- PR Newswire•3 months ago
SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
JERSEY CITY, N.J., April 8, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today commended the New York Times for its reporting on Candida auris and the major global health issues caused by drug-resistant pathogens. The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs.
- PR Newswire•4 months ago
SCYNEXIS's Ibrexafungerp Shows Favorable Clinical Activity in Resistant Fungal Infections, Including Candida auris Cases from the CARES Study, in Data to be Presented at the 29th ECCMID
Six presentations will provide additional evidence of the potent and broad antifungal activity of oral ibrexafungerp, including new clinical case studies from the CARES and FURI trials as well as promising ...
- PR Newswire•4 months ago
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
JERSEY CITY, N.J. , April 1, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today ...
- PR Newswire•4 months ago
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Phase 3 VANISH program underway, evaluating oral ibrexafungerp for the treatment of acute VVC; anticipate top-line data in the first half of 2020 with NDA submission in the second half of 2020 Oral ibrexafungerp ...
- PR Newswire•4 months ago
SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note
JERSEY CITY, N.J., March 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate principal amount of 6.0% convertible senior note due 2025 (the "note"). The note was sold in a private offering to Puissance Capital Management pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act").
- Simply Wall St.•5 months ago
Do Institutions Own Shares In SCYNEXIS, Inc. (NASDAQ:SCYX)?
A look at the shareholders of SCYNEXIS, Inc. (NASDAQ:SCYX) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owningRead More...
- PR Newswire•5 months ago
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Oral ibrexafungerp demonstrates potent antifungal activity against Pneumocystis in vivo Ibrexafungerp's broad spectrum activity and flexibility of oral administration highlight its potential utility as ...
- ACCESSWIRE•6 months ago
4 Biotech Stocks Making Moves On Thursday (1/31/19)
Premier Health Group (OTC:PHGRF) (CSE:PHGI), SCYNEXIS Inc (SCYX), Geron Corporation (GERN), and Fortress Biotech Inc (FBIO) represent four biotech companies creating new treatment technologies aimed to ensure that patients get the therapies best suited to their needs. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.
